ArticleJournal of thoracic disease2026
Development of a risk scoring model for predicting visceral pleural invasion in clinical stage T1N0M0 lung adenocarcinoma.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visceral pleural invasion (VPI) significantly impacts the staging and prognosis of non-small cell lung cancer (NSCLC). Accurate preoperative prediction of VPI remains challenging owing to the limitations of current imaging-based approaches. In this study, we aimed to develop and validate a risk prediction model for VPI using pleural carcinoembryonic antigen (CEA), maximum standardized uptake value (SUVmax), and nodule type. Methods: In this retrospective study, we analyzed patients with NSCLC and pleural contact who underwent surgery between 2017 and 2024. Pleural carcinoembryonic antigen (pCEA), SUVmax, and nodule type were identified as independent predictors of VPI using multivariable logistic regression. A risk-scoring model was developed and validated using independent cohorts. Results: In the multivariate analysis, elevated pCEA [odds ratio (OR), 3.00; 95% confidence interval (CI): 1.14-7.87; P=0.02], elevated SUVmax (OR, 5.25; 95% CI: 1.90-14.50; P=0.001), and nodule type (OR, 3.89; 95% CI: 1.42-10.68; P=0.008) were identified as independent risk factors for VPI. The model assigned scores based on these variables, with higher scores correlating with an increased probability of VPI. In the validation cohort of 95 patients, VPI probabilities ranged from 0% for a score of 0 to 69.2% for a score of 5. The model demonstrated strong predictive performance, achieving an area under the curve of 0.829 (95% CI: 0.7378-0.9200), a sensitivity of 79.2% (95% CI: 0.6250-0.9177), a specificity of 71.8% (95% CI: 0.6056-0.8310), and a positive predictive value of 51.3%. Conclusions: The proposed VPI risk model serves as a practical and accurate tool for preoperative VPI prediction, thereby enhancing clinical staging and enabling personalized surgical planning. The incorporation of pCEA emphasizes its potential clinical utility. However, external validation is necessary to establish its broader applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.